IR Portal for Veloxis Pharmaceuticals
OMX Copenhagen: VELO.CO
Seneste Kurs: 0,61
-6,15
Branche: Sundhed
RESSOURCER
7/3 2012Webcast 2011 annual report 
10/11 2011Q3 2011 webcast
21/6 2011Phase 3 Study Results Investor Conference
10/11 2011Q3 2011 webcast
21/6 2011Phase 3 Study Results Investor Conference
7/3 2012Presentation 2011 report
10/11 2011Q3 2011 presentation
9/8 20112011 Canaccord Genuity Growth Conference
10/11 2011Q3 2011 presentation
9/8 20112011 Canaccord Genuity Growth Conference
Senest opdateret 1/5 2012
VIRKSOMHEDSBESKRIVELSE:
Veloxis is a specialty pharmaceutical company. Clinical development is the core of our efforts to develop a product portfolio which includes the Company\'s lead product candidate, LCP‐Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis\' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
For further information, please visit www.veloxis.com.
INVESTOR RELATIONS KONTAKT
CFO
e-mail:
Senest opdateret 26/1 2012
FINANSIELLE TAL
| DKK’000 | 2011 | 2010 | 2009 |
|---|---|---|---|
| Revenue | 0.00 | 1.496 | 2.476 |
| Research and development costs | -222.053 | -210.426 | -210.140 |
| Administrative expenses | -47.814 | -52.198 | -62.381 |
| Operating profit (EBIT) | -269.867 | -272.022 | -279.534 |
| Net financial items | 16.048 | -759 | 8.540 |
| Net profit/loss for the year | -252.819 | -274.206 | -270.994 |
| Cash and cash equivalents at period end | 297.727 | 531.519 | 333.429 |
| Cash flow from operations | -234.637 | -238.148 | -251.158 |
| Total assets | 320.927 | 562.906 | 379.269 |
| Total equity | 255.900 | 498.238 | 317.281 |
| Total number of shares in thousands | 452.542 | 452.543 | 56.288 |
| EPS | -0,56 | -2,84 | -4,80 |
| BVPS | 0,57 | 1,20 | 5,90 |
| Average number of employees | 52 | 59 | 93 |
Senest opdateret 1/5 2012
The net loss is likewise expected to be in the range of DKK 250 – 280 million.
Forventet: 2011
Forventet: 2011
The net loss is likewise expected to be in the range of DKK 250 – 280 million.
Forventet: 2011
Forventet: 2011
The Company’s 31 December 2011 cash position is expected to be in the range of DKK 250 - 300 million.
Forventet: 2011
Forventet: 2011
Senest opdateret 23/6 2011
Handelsbanken
Peter Sehested
Peter Sehested
Senest opdateret 26/1 2012
Dr. William J. Polvino, M.D.
CEO
Mr. Peter G. Nielsen, M.Sc
Executive Vice President of Pharmaceutical Development
and Chemistry Manufacturing & Control
Johnny Stilou
Chief Financial officer
Timothy C. Melkus
Senior Vice President, Development Operations
Senest opdateret 26/1 2012
BEGIVENHEDER
Senest opdateret 25/5 2012
Senest opdateret 7/3 2012
Aktiekurs for Veloxis Pharmaceuticals
Du skal opdatere din Flash Player for at se dette indhold
DINE MULIGHEDER
| Dit kursmål: ingen |
| Gennemsnitligt kursmål (AVG): 1,00 (2) |
| Hvor vil Veloxis Pharmaceuticals lukke fra deres nuværende pris? Over  eller under  den nuværende kurs? |
|||
| Om en måned |
Om tre måneder |
Om seks måneder |
Om et år |
|
Brugernes anbefaling
SALG
KØB
|
|||
SKRIV INDLÆG
saving..
;){kind=link}
;){kind=link}